Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1790.30 | 29,575 Cr | 34.82 | 3.09 | 1.00 | 8.27 | 12.46 | 7.18 | |
996.85 | 21,089 Cr | 64.06 | 9.29 | 0.00 | 12.62 | 16.34 | 9.99 | |
1369.00 | 18,886 Cr | 43.26 | 5.37 | 0.53 | 13.45 | 14.38 | 6.57 | |
1686.70 | 12,732 Cr | 20.96 | 4.03 | 0.36 | 18.64 | 23.29 | 17.76 | |
770.25 | 12,671 Cr | 88.74 | 11.04 | 0.00 | 26.49 | 22.49 | 11.57 | |
172.80 | 7,769 Cr | 21.71 | 2.89 | 0.47 | 13.08 | 16.13 | 10.51 | |
324.75 | 6,330 Cr | 39.39 | 2.60 | 0.15 | 6.35 | 8.41 | 4.29 |
Sai Life Sciences Ltd (SAILIFE) is currently trading at 1,007.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sai Life Sciences is an integrated CRDMO providing end-to-end discovery, development and commercial manufacturing services to global pharmaceutical and biotechnology innovators, operating discovery and R&D labs in Boston and Manchester plus large GMP manufacturing and R&D campuses in India. Q3 FY26 revenue was ₹556 crore (+27% YoY) and 9MFY26 revenue reached ₹1,590 crore (+43% YoY); EBITDA margin expanded to 34% in Q3 and 30% for 9MFY26, driven by operating leverage on employee costs and improved material margins. The company is executing a substantial expansion program (FY26 capex plan ~₹700 crore, ₹405 crore invested so far) to nearly double reactor capacity to 1,150 KL and add major Process R&D, peptide pilot, and OEB‑6 containment labs, targeting commercial scale for new modalities. Sai is shifting beyond commodity CDMO work into next-generation modalities—peptides, ADC payloads, oligonucleotides and TPDs—while embedding AI/ML, photochemistry, flow, and electrochemistry into discovery and CMC workflows to accelerate timelines and win strategic, large‑pharma partnerships.
Over the past 52 weeks, Sai Life Sciences Ltd has traded between a low of ₹635.30 and a high of ₹1,014.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sai Life Sciences Ltd has a market capitalization of approximately 21,088.93. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sai Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 64.06 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 21,088.93 Cr, Sai Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sai Life Sciences Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sai Life Sciences Ltd is 64.06. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a ₹10,000 crore strategy aimed at making India a global hub for biopharma manufacturing, focusing on biologics and biosimilars over the next five years.
Bearish
6
Neutral
3
Bullish
5
Bearish
6
Neutral
3
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Sai Life Sciences is an integrated CRDMO providing end-to-end discovery, development and commercial manufacturing services to global pharmaceutical and biotechnology innovators, operating discovery and R&D labs in Boston and Manchester plus large GMP manufacturing and R&D campuses in India.
Q3 FY26 revenue was ₹556 crore (+27% YoY) and 9MFY26 revenue reached ₹1,590 crore (+43% YoY); EBITDA margin expanded to 34% in Q3 and 30% for 9MFY26, driven by operating leverage on employee costs and improved material margins.
The company is executing a substantial expansion program (FY26 capex plan ~₹700 crore, ₹405 crore invested so far) to nearly double reactor capacity to 1,150 KL and add major Process R&D, peptide pilot, and OEB‑6 containment labs, targeting commercial scale for new modalities.
Sai is shifting beyond commodity CDMO work into next-generation modalities—peptides, ADC payloads, oligonucleotides and TPDs—while embedding AI/ML, photochemistry, flow, and electrochemistry into discovery and CMC workflows to accelerate timelines and win strategic, large‑pharma partnerships.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
21,089 Cr
High Risk
64.1
44.0
4.1
9.3
1,008.65
635.30
Sales CAGR
Profit CAGR
ROE
ROCE
Credit Rating
ICRA (letter dated Feb 26, 2026) assigned [ICRA]AA(Stable) to Rs.550 Cr long‑term fund‑based limits and [ICRA]A1+ to Rs.218.6 Cr short‑term non‑fund limits of Sai Life Sciences (total Rs.768.6 Cr).
Credit Rating
ICRA has assigned [ICRA]AA (Stable) to Rs.550 Cr long‑term fund limits and [ICRA]A1+ to Rs.218.6 Cr short‑term non‑fund limits (total Rs.768.6 Cr) for Sai Life Sciences on 26 Feb 2026.
